Search

Your search keyword '"Katzenstein, T"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Katzenstein, T" Remove constraint Author: "Katzenstein, T" Topic anti-hiv agents Remove constraint Topic: anti-hiv agents
29 results on '"Katzenstein, T"'

Search Results

1. Phylogeny and resistance profiles of HIV-1 POL sequences from rectal biopsies and blood.

3. 2B4 expression on natural killer cells increases in HIV-1 infected patients followed prospectively during highly active antiretroviral therapy.

4. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

5. T-cell receptor excisional circles, telomere length, proliferation and apoptosis in peripheral blood mononuclear cells of human immunodeficiency virus-infected individuals after 18 months of treatment induced viral suppression.

6. [No development of HIV infection after transfusion with HIV-contaminated blood and postexposure antiviral prevention].

7. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir.

8. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.

9. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.

10. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

11. Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment.

12. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.

13. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

14. Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group.

15. Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.

16. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

17. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

18. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

19. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

20. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

21. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

22. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

23. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

24. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

25. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

26. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

27. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

28. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

29. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients

Catalog

Books, media, physical & digital resources